Study of Pazopanib and Doxil in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
This study has been completed.
Information provided by (Responsible Party):
SCRI Development Innovations, LLC
First received: December 17, 2009
Last updated: July 1, 2014
Last verified: July 2014
In this study, patients with relapsed or refractory ovarian cancer will receive treatment with pazopanib and liposomal doxorubicin (Doxil) until disease progression or unacceptable toxicity occurs. The Phase I portion will define the dose limiting toxicity (DLT) of pazopanib and liposomal doxorubicin when administered in combination. Once the maximum tolerated dose has been identified in the Phase I portion, the Phase II portion will evaluate efficacy and safety of this combination in the same patient population.
Fallopian Tube Cancer
||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||A Phase I/II Study of the Combination of Pazopanib and Liposomal Doxorubicin (Doxil) in Patients With Advanced Relapsed Platinum-Sensitive or Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma
Primary Outcome Measures:
- Phase I: To define the optimal doses of pazopanib and liposomal doxorubicin when administered in combination to patients with relapsed/refractory ovarian cancer [ Time Frame: 18 months ] [ Designated as safety issue: Yes ]
- Phase II: To evaluate the response rate and progression-free survival of patients with relapsed/refractory ovarian cancer when treated with pazopanib and liposomal doxorubicin [ Time Frame: 18 months ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- To determine the overall survival of patients with relapsed/refractory ovarian cancer following treatment with pazopanib and liposomal doxorubicin. [ Time Frame: 18 months ] [ Designated as safety issue: No ]
- To determine the efficacy of pazopanib/liposomal doxorubicin (response rate, progression-free survival, overall survival) separately in the subsets of patients with platinum-sensitive and platinum-refractory ovarian carcinoma [ Time Frame: 18 months ] [ Designated as safety issue: No ]
- To evaluate the toxicity of the combination of pazopanib and liposomal doxorubicin [ Time Frame: 18 months ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2012 (Final data collection date for primary outcome measure)
Systemic therapy with pazopanib and liposomal doxorubicin (Doxil). Single-agent pazopanib will be given for a 7 day run-in period, followed by a combination of pazopanib and liposomal doxorubicin administered in 28-day treatment cycles. Cycles will continue until disease progression, unacceptable toxicity or withdrawal.
All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
- Systemic therapy
Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
- Systemic therapy
- Liposomal doxorubicin
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Histologically or cytologically confirmed diagnosis of epithelial ovarian carcinoma (FIGO Stage II to IV), primary peritoneal cancer or fallopian tube.
- One or 2 previous chemotherapy regimens for advanced ovarian cancer. At least one of these regimens must have contained a platinum agent.
- Patients who are platinum-resistant (relapse <6 months after completing a platinum-containing regimen) or platinum sensitive (relapse ≥ 6 months after platinum-containing regimen) are eligible.
- Radiographically documented progression per RECIST criteria (version 1.1) or progression of CA-125 during or subsequent to the last chemotherapy regimen.
- Measurable disease (RECIST criteria) or evaluable disease with elevated CA-125 level. Patients with normal CT scans and elevated CA-125 levels as the only indication of disease are not eligible. ECOG performance status of 0 or 1.
- Normal left ventricular ejection fraction (LVEF) according to institutional standards.
- Adequate recovery from recent surgery. At least 1 week must have elapsed from the time of a minor surgery (with the exception of portacath placement); at least 4 weeks must have elapsed from the time of a major surgery.
Laboratory values as follows:
- Absolute neutrophil count (ANC) ≥1500/μL
- Hemoglobin (Hgb) ≥9g/dL. Patients may not have received RBC transfusions within 7 days of screening assessment.
- Platelets ≥100,000/L
- AST or ALT must be <2.5 x ULN (concomitant elevations in bilirubin and AST/ALT >1.0 x ULN are not permitted).
- Total bilirubin <1.5 x the institutional ULN (if Gilberts syndrome, direct bilirubin ≤1.5 x ULN)
- International normalized ratio (INR) 1.2 and activated partial thromboplastin time (aPTT) 1.2 the ULN (except for patients receiving anti-coagulation therapy)
- Cr ≤ 1.5 x ULN. If Cr >1.5 x ULN, then calculated creatinine clearance must be ≥50 mL/min
- Urine protein creatinine (UPC) ratio ≤1.0 at screening OR Urine dipstick for proteinuria <2+ (patients discovered to have 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate <1g of protein in 24 hours to be eligible).
- Patients must be 18 years of age.
- Life expectancy of ≥12 weeks.
- Patient must be accessible for treatment and follow-up.
- Patients must be able to understand the investigational nature of this study and give written informed consent prior to study entry.
- Females of non-childbearing potential (i.e., physiologically incapable of becoming pregnant), include a female who has had: a hysterectomy, a bilateral oophorectomy, a bilateral tubal ligation, or is post-menopausal. Patients not using hormone replacement therapy (HRT) must have experienced total cessation of menses for ≥1 year and be ≥45 years old, or in questionable cases, have a follicle stimulating hormone (FSH) value >40 mIU/mL and an estradiol value <40pg/mL. Patients using HRT must have experienced total cessation of menses for ≥1 year and be ≥45 years old, or have had documented evidence of menopause based on FSH and estradiol prior to the initiation of HRT.
- Women of childbearing potential must have a negative serum or urine pregnancy test performed ≤14 days prior to start of treatment. Women of childbearing potential must use effective birth control measures during treatment. Acceptable contraceptive methods include: 1) an intrauterine device with a documented failure rate of ≤1% per year, 2) a vasectomized partner who is sterile prior to the patient‟s entry and is the sole sexual partner for that female, 3) abstinence 14 days prior to study entry, throughout the dosing period, and for at least 21 days after the last dose of protocol therapy, 4) double-barrier contraception, or 5) oral contraception. If a woman becomes pregnant or suspects she is pregnant while participating in this study, she must agree to inform her treating physician immediately.
- Patients may not have received either investigational or marketed agents, which act by primary anti-angiogenic mechanisms (i.e. bevacizumab).
- Prior treatment with liposomal doxorubicin.
- Patients with brain metastases. (Baseline imaging required only if clinically indicated).
- Patients with known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.
- Patients with hemoptysis within 6 weeks of first dose of study drug.
- Patients who are pregnant or breast feeding.
Impaired cardiac function including any of the following conditions within the past 6 months:
- NYHA Class II, III or IV heart failure.
- QTc prolongation or other significant ECG abnormalities.
- Myocardial infarction or unstable angina
- Coronary artery bypass graft surgery
- Symptomatic peripheral vascular disease
- History of sustained ventricular tachycardia.
Patients must not have taken any potent CYP3A4 inhibitors <= 14 days prior to enrollment including but not limited to:
• ketoconazole, itraconazole, troleandomycin, clarithromycin, erythromycin, ritonavir, indinavir, nelfinavir, saquinavir, amprenavir, nefazodone, fluvoxamine, diltiazem, verapamil, mibefradil, cimetidine, cyclosporine, and grapefruit juice.
- Uncontrolled hypertension (systolic blood pressure [BP] >180 or diastolic BP >100mm Hg) or uncontrolled cardiac arrhythmias (Patients with hypertension controlled by antihypertensive therapies are eligible.)
- History of cerebrovascular accident (CVA), MI within 12 months or venous thrombosis within 12 weeks. (Patients with previous history of venous thrombosis on a stable dose of anticoagulation are allowed.)
- Concurrent severe, intercurrent illness including, but not limited to, ongoing or active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.
- Inability to swallow whole tablets.
- Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter drug absorption (e.g., active inflammatory bowel disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or significant small bowel resection).
- Mental condition that would prevent patient comprehension of the nature of, and risk associated with, the study.
- Use of any non-approved or investigational agent <= 30 days prior to administration of the first dose of study drug. Patients may not receive any other investigational or anti-cancer treatments while participating in this study.
- Past or current history of neoplasm other than the entry diagnosis with the exception of treated non-melanoma skin cancer or carcinoma in situ of the cervix, or other cancers cured by local therapy alone and a DFS >= 5 years.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01035658
|Florida Cancer Specialists
|Fort Myers, Florida, United States, 33901 |
|Florida Hospital Cancer Insitute
|Orlando, Florida, United States, 32804 |
|Oncology Hematology Care
|Cincinnati, Ohio, United States, 45242 |
|Tennessee Oncology, PLLC
|Nashville, Tennessee, United States, 37023 |
SCRI Development Innovations, LLC
||T.Michael Numnum, MD
||SCRI Development Innovations, LLC
No publications provided
||SCRI Development Innovations, LLC
History of Changes
|Other Study ID Numbers:
||SCRI GYN 26
|Study First Received:
||December 17, 2009
||July 1, 2014
||United States: Food and Drug Administration
Keywords provided by SCRI Development Innovations, LLC:
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on October 23, 2014
Fallopian Tube Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Molecular Mechanisms of Pharmacological Action
Topoisomerase II Inhibitors